EA029180B1 - Лекарственная форма лакозамида для приема один раз в сутки - Google Patents

Лекарственная форма лакозамида для приема один раз в сутки Download PDF

Info

Publication number
EA029180B1
EA029180B1 EA201390804A EA201390804A EA029180B1 EA 029180 B1 EA029180 B1 EA 029180B1 EA 201390804 A EA201390804 A EA 201390804A EA 201390804 A EA201390804 A EA 201390804A EA 029180 B1 EA029180 B1 EA 029180B1
Authority
EA
Eurasian Patent Office
Prior art keywords
lacosamide
dosage form
release
amount
weight
Prior art date
Application number
EA201390804A
Other languages
English (en)
Russian (ru)
Other versions
EA201390804A1 (ru
Inventor
Вилли Кавелло
Мартин Александер Шуберт
Original Assignee
Юсб Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA029180(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP10193561A external-priority patent/EP2468261A1/en
Application filed by Юсб Фарма Гмбх filed Critical Юсб Фарма Гмбх
Publication of EA201390804A1 publication Critical patent/EA201390804A1/ru
Publication of EA029180B1 publication Critical patent/EA029180B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201390804A 2010-12-02 2011-12-01 Лекарственная форма лакозамида для приема один раз в сутки EA029180B1 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US41915310P 2010-12-02 2010-12-02
US41915810P 2010-12-02 2010-12-02
EP10193561A EP2468261A1 (en) 2010-12-02 2010-12-02 Formulation of lacosamide
EP10193559 2010-12-02
US201161444447P 2011-02-18 2011-02-18
US201161444439P 2011-02-18 2011-02-18
US201161485361P 2011-05-12 2011-05-12
US201161485354P 2011-05-12 2011-05-12
PCT/EP2011/006027 WO2012072256A2 (en) 2010-12-02 2011-12-01 Once daily formulation of lacosamide

Publications (2)

Publication Number Publication Date
EA201390804A1 EA201390804A1 (ru) 2013-10-30
EA029180B1 true EA029180B1 (ru) 2018-02-28

Family

ID=46172318

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390804A EA029180B1 (ru) 2010-12-02 2011-12-01 Лекарственная форма лакозамида для приема один раз в сутки

Country Status (14)

Country Link
US (4) US20130251813A1 (pt-pt)
EP (3) EP2646001A2 (pt-pt)
JP (2) JP6027539B2 (pt-pt)
KR (1) KR101980386B1 (pt-pt)
CN (1) CN103561727B (pt-pt)
AU (1) AU2011335415B2 (pt-pt)
BR (1) BR112013013525A2 (pt-pt)
CA (1) CA2817654A1 (pt-pt)
EA (1) EA029180B1 (pt-pt)
IL (1) IL226231B (pt-pt)
MX (1) MX2013005974A (pt-pt)
NZ (1) NZ610701A (pt-pt)
WO (2) WO2012072256A2 (pt-pt)
ZA (1) ZA201303289B (pt-pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA027836B1 (ru) 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20120308662A1 (en) * 2011-06-01 2012-12-06 Nitto Denko Corporation Particulate preparation and method for producing the same
US8779355B2 (en) 2011-12-28 2014-07-15 Quest Diagnostics Investments, Inc. Methods for detecting lacosamide by mass spectrometry
KR101732731B1 (ko) 2013-04-02 2017-05-08 주식회사 바이오파마티스 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물
WO2014180895A1 (en) * 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of lacosamide
EP3074004A2 (en) * 2013-11-29 2016-10-05 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
EP2878296A1 (en) 2013-11-29 2015-06-03 UCB Pharma GmbH Pharmaceutical composition comprising lacosamide and levetiracetam
CA2948852C (en) * 2014-05-16 2023-03-14 Vivus, Inc. Orally administrable formulations for the controlled release of a pharmacologically active agent
US20180021307A1 (en) 2015-02-20 2018-01-25 Ucb Biopharma Sprl Combination Treatment
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
BR112018012870A2 (pt) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise
WO2018062955A1 (ko) * 2016-09-29 2018-04-05 에스케이케미칼(주) 라코사미드 서방성 제제
CN106551900A (zh) * 2016-12-05 2017-04-05 北京万全德众医药生物技术有限公司 一种拉科酰胺口服溶液及其制备工艺
EP4272827A3 (en) 2016-12-09 2024-01-24 Alexza Pharmaceuticals, Inc. Method of treating epilepsy
KR102083241B1 (ko) * 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물
CN110833528A (zh) * 2018-08-17 2020-02-25 北京万全德众医药生物技术有限公司 一种拉科酰胺脂质体冻干粉针剂及其制备方法
CN109010301B (zh) * 2018-09-05 2021-01-26 上海上药第一生化药业有限公司 一种拉考沙胺晶型ii片剂及其制备方法和应用
EP3981390A4 (en) * 2019-06-06 2023-01-25 Shanghai Aucta Pharmaceuticals Co., Ltd. LACOSAMIDE PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL PREPARATION THEREOF
CN112022804A (zh) * 2020-09-28 2020-12-04 健民药业集团股份有限公司 一种拉考沙胺口服溶液及制备方法
EP4309648A1 (en) * 2021-03-17 2024-01-24 Shanghai Yonsun Biotechnology Co., Ltd. Lacosamide pharmaceutical composition, preparation method for same, and applications thereof
WO2024054987A1 (en) * 2022-09-08 2024-03-14 The Children's Hospital Of Philadlphia Gpcr latrophilin-3 as biomarker for detecting increased risk for mild brain injury and methods of use thereof for diagnosis and treatment of the same
CN115581676A (zh) * 2022-09-30 2023-01-10 澳美制药(苏州)有限公司 拉考沙胺片剂及其制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2010060624A2 (de) * 2008-11-27 2010-06-03 Ratiopharm Gmbh Trockenverarbeitung und neue formen von lacosamid
WO2011055385A1 (en) * 2009-11-03 2011-05-12 Lupin Limited Modified release formulation of lacosamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038522B1 (en) 1996-03-15 2004-06-02 Research Corporation Technologies, Inc Anticonvulsant enantiomeric amino acid derivatives
AU744899B2 (en) 1997-07-15 2002-03-07 Research Corporation Technologies, Inc. Amino acid derivatives useful to treat stroke
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
DE60100055T2 (de) 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
JP4664924B2 (ja) 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
CA2562937A1 (en) 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
AU2005276634B2 (en) 2004-08-27 2011-03-24 Ucb Pharma Gmbh Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
JP2006124385A (ja) * 2004-09-30 2006-05-18 Takeda Chem Ind Ltd 放出制御製剤
US20060105663A1 (en) * 2004-10-04 2006-05-18 Stefan Greulich Polymer assemblies with decorative surfaces
WO2006080029A1 (en) * 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
CA2595330A1 (en) 2005-01-28 2006-08-03 Schwarz Pharma Ag Spm 927 for add-on therapy of schizophrenia
WO2007008752A2 (en) * 2005-07-07 2007-01-18 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
EA027836B1 (ru) 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
EP1925314A1 (en) 2006-11-22 2008-05-28 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP1920780A1 (en) 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US20120003307A1 (en) 2007-11-29 2012-01-05 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
US20090143362A1 (en) 2007-12-04 2009-06-04 Barabde Umesh Vinayakrao Carbamazepine formulations
KR100980999B1 (ko) * 2008-11-28 2010-09-07 기아자동차주식회사 차량용 시거라이터조립체
WO2010148300A1 (en) 2009-06-19 2010-12-23 The University Of North Carolina At Chapel Hill Methods of treatment of neurological disorders
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2010060624A2 (de) * 2008-11-27 2010-06-03 Ratiopharm Gmbh Trockenverarbeitung und neue formen von lacosamid
WO2011055385A1 (en) * 2009-11-03 2011-05-12 Lupin Limited Modified release formulation of lacosamide

Also Published As

Publication number Publication date
JP6027539B2 (ja) 2016-11-16
MX2013005974A (es) 2013-07-29
WO2012072256A3 (en) 2014-01-23
CA2817654A1 (en) 2012-06-07
EA201390804A1 (ru) 2013-10-30
US20130251813A1 (en) 2013-09-26
BR112013013525A2 (pt) 2016-10-18
ZA201303289B (en) 2014-02-26
US20190054009A1 (en) 2019-02-21
CN103561727B (zh) 2018-03-27
KR101980386B1 (ko) 2019-05-20
AU2011335415B2 (en) 2016-05-19
IL226231A0 (en) 2013-07-31
IL226231B (en) 2018-01-31
WO2012084126A2 (en) 2012-06-28
JP2017031206A (ja) 2017-02-09
WO2012084126A3 (en) 2013-05-02
NZ610701A (en) 2015-06-26
EP2645997A2 (en) 2013-10-09
EP3766485A1 (en) 2021-01-20
EP2645997B1 (en) 2022-08-10
JP6357687B2 (ja) 2018-07-18
KR20150034579A (ko) 2015-04-03
EP2646001A2 (en) 2013-10-09
US20190008758A1 (en) 2019-01-10
WO2012072256A2 (en) 2012-06-07
CN103561727A (zh) 2014-02-05
US20150104507A1 (en) 2015-04-16
JP2013545762A (ja) 2013-12-26
AU2011335415A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
EA029180B1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
US10149818B2 (en) Daily formulation of lacosamide
KR20100119539A (ko) 다이펜하이드라민을 포함하는 경구 분해성 정제
CA2611430A1 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
EP2701689B1 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
JP2024041898A (ja) 高用量の放出調節フペルジン製剤の使用
AU2020389425A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
US20150366850A1 (en) Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
DK2277511T3 (en) Pharmaceutical Compositions of sustained-release Levetiracetam
EP2298290A1 (en) Controlled release composition comprising levetiracetam
WO2015063670A1 (en) Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
KR102065090B1 (ko) 레베티라세탐 또는 이의 약제학적으로 허용되는 염을 함유하는 서방성 제제 및 이의 제조방법
CA3161908A1 (en) Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
WO2014167439A1 (en) Modified release pharmaceutical compositions of topiramate or salts thereof
EA044464B1 (ru) Таблетка для ингибирования полиаденозин дифосфат рибоза полимеразы (parp)
TR201605993A1 (tr) Gastroi̇ntesti̇nal hastaliklarin tedavi̇si̇nde kullanilan farmasöti̇k formülasyonlar
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU